Background {#mgg3206-sec-0005}
==========

The North American Hutterite population is comprised of approximately 45,000 individuals living on colonies in the prairies of Canada and the United States (<http://www.hutterites.org/>). The Hutterites emerged during the Protestant Reformation in the 16th century as a religious isolate who believed in adult baptism (anabaptist), communal living including sharing of goods, and nonviolence (Hostetler [1974](#mgg3206-bib-0024){ref-type="ref"}). Religious persecution led to their migration across central Europe and dramatic fluctuations in their population numbers. These population bottlenecks, coupled with reproductive isolation and population expansion, have resulted in a distinct group of genetic disorders that are overrepresented and in some cases unique to the Hutterites (Boycott et al. [2008](#mgg3206-bib-0008){ref-type="ref"}).

Both demographic and genetic studies indicate that shortly after their founding, individuals from South Tyrol in Austria, Germany, and Switzerland settled to form a thriving Hutterite population in Moravia (Hostetler [1974](#mgg3206-bib-0024){ref-type="ref"}). In 1874, continued religious persecution led 1265 Hutterites to emigrate to the United States (Eaton and Mayer [1953](#mgg3206-bib-0015){ref-type="ref"}) where 443 Hutterites settled into three colonies, forming the basis of the Schmiedeleut, Lehrerleut, and Dariusleut divisions of Hutterite population structure. Those Hutterites who did not join the colonies integrated into the general population of the United States. During the First World War, Hutterites from the colonies moved to the Canadian Prairie provinces of Manitoba, Alberta, and Saskatchewan. Since that time, the Hutterites have been one of the most rapidly growing populations in the world, and have formed 107 colonies in Manitoba, 60 in Saskatchewan, 168 in Alberta, 2 in British Columbia, 54 in South Dakota, 7 in North Dakota, 9 in Minnesota, 50 in Montana, and 5 in Washington (<http://www.hutterites.org/>).

It is estimated that 89 individuals founded today\'s Hutterites (Nimgaonkar et al. [2000](#mgg3206-bib-0033){ref-type="ref"}). The decreased genetic heterogeneity in the population, together with large family size and meticulous genealogical records, has greatly facilitated the identification of disease genes in this population through identity by descent mapping studies. As a result, the causative gene has been identified for at least 35 autosomal recessive disorders, and still others remain to be found (Boycott et al. [2008](#mgg3206-bib-0008){ref-type="ref"}; Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"}).

The same features that have facilitated the identification of disease genes have also resulted in an increased incidence of several genetic diseases, including some that are unique to the Hutterites. The carrier frequencies for a number of these disorders were recently examined in a large sample of Schmiedeleut Hutterites, and found to range from 1/6.5 to 1/48 in this group (Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"}). Given the high carrier frequencies, the preexisting knowledge of the molecular basis of disease in this population, and strong endorsement from the Manitoba Hutterite ministers and constituents (personal communication, S. Maendel and Hutterite Brethren), we developed a screening tool that may be used by this population for family planning. With this in mind, herein, we describe the design and testing of a DNA chip that allows for the analysis of carrier status for 30 autosomal recessive conditions in the Hutterite population.

Materials and Methods {#mgg3206-sec-0006}
=====================

Ethical compliance {#mgg3206-sec-0007}
------------------

The University of Chicago Institutional Review Board provided approval to use the 12 DNA samples from the Hutterite population in an anonymized fashion.

Disease identification for DNA chip {#mgg3206-sec-0008}
-----------------------------------

A list of genetic disorders described in the Hutterite population, and their molecular basis if known, was developed based on an exhaustive literature search and consultation with clinicians and researchers working on genetic disorders in this population. An expert panel made up of clinical geneticists, laboratory specialists, and basic scientists reviewed the list and selected autosomal recessive conditions that have clearly defined mutations and are clinically significant, for inclusion on the chip.

DNA chip construction {#mgg3206-sec-0009}
---------------------

The DNA chip was developed in consultation with Asper Biotech (<http://www.asperbio.com/?s=Hutterite>) on a fee‐for‐service basis. Oligonucleotides were designed for using the array primer extension (APEX) methodology which, in brief, utilizes Sanger sequencing that is limited to the addition of a single nucleotide to a primer on a microarray platform (Jaakson et al. [2003](#mgg3206-bib-0027){ref-type="ref"}). The APEX method has been used extensively in a wide variety of clinical scenarios (Henderson et al. [2007](#mgg3206-bib-0022){ref-type="ref"}). During the technical validation stage, control DNA samples containing mutations of the diseases of interest, were provided, without blinding, to verify the mutation detection. Mutations can be added to this chip for a fee, and the service for the analysis of samples using the chip is CLIA and ISO15189 certified.

DNA samples {#mgg3206-sec-0010}
-----------

DNA samples from 59 controls known to be homozygous or heterozygous for a specific mutation were submitted to Asper Biotech for analysis, after all identifying information was removed. As the chip simultaneously detects 32 mutations, it was anticipated that mutations, other than the known ones, would be detected. In addition, 12 DNA samples from Schmiedeleut individuals, which had been analyzed as part of previous studies, were provided in a blinded fashion to assess the performance of the chip (Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"}).

Results {#mgg3206-sec-0011}
=======

Chip construction {#mgg3206-sec-0012}
-----------------

An expert panel identified 30 autosomal recessive conditions in the Hutterite population to include for testing on a diagnostic chip (Table [1](#mgg3206-tbl-0001){ref-type="table-wrap"}). The chip was constructed with oligonucleotides designed by Asper Biotech. To assess the specificity of the chip, 59 controls known to be heterozygous or homozygous for each mutation were sent for testing of the chip by Asper. As no known control was available for the *SLC5A5* c.1183G\>A (p.G395R) mutation, which causes thyroid dyshormonogenesis I (also known as iodide transport defect), a synthetic DNA fragment was generated by Asper Biotech for specificity checks.

###### 

Autosomal recessive disorders, and corresponding mutations, that have been included on the chip. Carrier frequencies were included if the mutation was either observed at least once in samples sent to Asper (Observed Freq.) and/or referenced in the literature (Literature Freq.)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disorder                                      MIM      Phenotype                                                                                                                                                                                                    Gene         Mutation                                Leut[a](#mgg3206-note-0002){ref-type="fn"}   Observed Freq.[b](#mgg3206-note-0003){ref-type="fn"}   Literature Freq.[d](#mgg3206-note-0005){ref-type="fn"}   Ref.[f](#mgg3206-note-0007){ref-type="fn"}
  --------------------------------------------- -------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------ --------------------------------------- -------------------------------------------- ------------------------------------------------------ -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Arrhythmogenic cardiomyopathy                 610476   Biventricular disorder causing heart failure, intractable arrhythmias with risk of sudden death in young adults                                                                                              *DSC2*       c.1660C\>T (p.Q554X)                    D,L,S                                        1/8                                                    1/10.6                                                   (Gerull et al. [2013](#mgg3206-bib-0018){ref-type="ref"})

  Bardet--Biedl syndrome                        209900   Multisystem ciliopathy characterized by obesity, Retinitis pigmentosa, syndactyly polydactyly, hypogonadism, renal failure, and variable intellectual disability                                             *BBS2*       c.472‐2A\>G                             D,S                                          1/13                                                   1/22--1/36                                               (Innes et al. [2010](#mgg3206-bib-0026){ref-type="ref"}; Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"})

  Beaulieu‐Boycott‐Innes syndrome               613680   Intellectual disability syndrome with microcephaly, characteristic facies and occasionally congenital heart or renal anomalies                                                                               *THOC6*      c.136G\>A (p.G46R)                      D                                            ‐[c](#mgg3206-note-0004){ref-type="fn"}                1/33--1/50                                               (Beaulieu et al. [2013](#mgg3206-bib-0004){ref-type="ref"}; Boycott et al. [2010](#mgg3206-bib-0009){ref-type="ref"})

  Bowen‐Conradi syndrome                        211180   Severe IUGR, characteristic facies with prominent nose and micrognathia, contractures, profound developmental delay early lethality                                                                          *EMG1*       c.257A\>G (p.D86G)                      D,L,S                                        1/21                                                   1/10                                                     (Armistead et al. [2009](#mgg3206-bib-0003){ref-type="ref"}; Lowry et al. [2003](#mgg3206-bib-0031){ref-type="ref"})

  Carnitine palmitoyltransferase 1 deficiency   212500   Inborn error of fat metabolism causing hypoketotic hypoglycemia and "Reye‐like" syndrome with stressors such as fever and illness. Effective treatment if identified on newborn screening                    *CPT1A*      c.2129 G\>A (p.G710E)                   D,S                                          1/16                                                   1/15                                                     (Prip‐Buus et al. [2001](#mgg3206-bib-0035){ref-type="ref"})

  Cerebellar atrophy, short stature                      Cerebellar hypoplasia, ataxia, short stature, global delay, and manganese deficiency                                                                                                                         *SLC39A8*    c.112G\>C (p.G38R)                      D,S                                          1/21                                                   Unknown[e](#mgg3206-note-0006){ref-type="fn"}            (Boycott et al. [2015](#mgg3206-bib-0010){ref-type="ref"})

  Combined pituitary hormone deficiency         262600   Deficiencies of growth hormone, thyroid hormone, gonadotropins, and occasionally +/− prolactin. Presents in infancy with FTT and growth failure.                                                             *PROP1*      c.301_302delAG (p.L102 fs)              D,L,S                                        --                                                     Unknown                                                  (Boycott et al. [2008](#mgg3206-bib-0008){ref-type="ref"}; Wu et al. [1998](#mgg3206-bib-0039){ref-type="ref"})

  Congenital hyperinsulinism                    256450   Presents usually with severe neonatal‐onset hyperinsulinemic hypoglycemia and seizures; may respond partially to diazoxide or may need pancreatic resection                                                  *ABCC8*      c.823‐7T\>A                             S                                            --                                                     Unknown                                                  Stanley PC

  Cranioectodermal dysplasia‐like                        Scaphocephaly with or without sagittal craniosynostosis, ectodermal anomalies, short stature, developmental delay                                                                                            *DPH1*       c.17T\>A (p.M6K)                        D                                            1/32                                                   Unknown                                                  (Loucks et al. [2015](#mgg3206-bib-0030){ref-type="ref"})

  Cystic fibrosis                               219700   Multisystem disorder with progressive lung disease and malaborption due to pancreatic insufficiency; newborn screening and early treatment recommended                                                       *CFTR*       c.3302T \>A (p.M1101K)\                 D,L,S\                                       1/16\                                                  1/13.5\                                                  (Zielenski et al. [1993](#mgg3206-bib-0042){ref-type="ref"}; Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"})
                                                                                                                                                                                                                                                                                   c.1521_1523delCTT (p.I507_F508del)      D,L,S                                        1/33                                                   1/45.5                                                   

  Dilated cardiomyopathy with ataxia syndrome   610198   Variable intellectual disability associated with gait and balance disturbance, short stature, genital anomalies in males, cardiomyopathy and arrhythmias often with 3‐methylglutaconic aciduria              *DNAJC19*    c.130‐1G\>C                             D,L,S                                        1/21                                                   1/36                                                     (Davey et al. [2006](#mgg3206-bib-0014){ref-type="ref"}; Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"})

  Hypophosphatasia                              241500   Only one report in Hutterite baby, disorder of skeletal mineralization, with variable age of onset, caused by deficiency of alkaline phosphatase activity. Clinical trials with ERT show promising results   *ALPL*       c.1001G\>A (p.G334D)                    D                                            --                                                     Unknown                                                  (Gibson et al. [2000](#mgg3206-bib-0019){ref-type="ref"})

  Joubert syndrome related disorder             614424   Hypotonia, global developmental delay/intellectual disability, renal anomalies, variable encephalocele, and polydactyly, molar tooth sign on MRI                                                             *TMEM237*    c.52C\>T (p.R18X)                       D,S                                          1/16                                                   1/12.5                                                   (Huang et al. [2011](#mgg3206-bib-0025){ref-type="ref"}; Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"}; Boycott et al. [2007](#mgg3206-bib-0007){ref-type="ref"})

  Leigh disease                                 256000   Severe disorder of energy metabolism with encephalopathy and loss of motor and cognitive skills                                                                                                              *NDUFS4*     c.393dupA (p.K131 fs)                   D,S                                          1/13                                                   Unknown                                                  (Boycott et al. [2008](#mgg3206-bib-0008){ref-type="ref"})

  Limb girdle muscular dystrophy 2H             254110   Slowly progressive late‐onset muscular dystrophy with mainly proximal weakness; not associated with cardiomyopathy                                                                                           *TRIM32*     c.1459G\>A (p.D487N)                    D,S                                          1/31                                                   1/6.5                                                    (Frosk et al. [2002](#mgg3206-bib-0016){ref-type="ref"}; Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"})

  Limb girdle muscular dystrophy 2I             607155   Proximal myopathy similar to LGMD2H but earlier age of onset, variable rate of progression, and cardiomyopathy which can be presenting manifestation                                                         *FKRP*       c.826C\>A (p.L276I)                     D,S                                          1/7                                                    1/9.5                                                    (Frosk et al. [2005](#mgg3206-bib-0017){ref-type="ref"}; Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"})

  Limb girdle muscular dystrophy 2S             615356   Muscular dystrophy with variable movement disorder and abnormal posturing of limbs; may have intellectual disability                                                                                         *TRAPPC11*   c.1287 + 5G\>A                          D,S                                          1/8                                                    1/14                                                     (Bogershausen et al. [2013](#mgg3206-bib-0005){ref-type="ref"})

  Methylmalonic aciduria                        251000   Severe inborn error with neonatal presentation of metabolic acidosis and hyperammonemia; isolated MMA 20 mut0 defect of methylmalonyl‐CoA mutase unresponsive to B12 and often fatal                         *MUT*        c.1420C\>T (p.R474X)                    D                                            1/63                                                   Unknown                                                  (Worgan et al. [2006](#mgg3206-bib-0038){ref-type="ref"})

  Nephronophthisis‐juvenile                     256100   Cystic renal disease‐causing renal failure in childhood or adolescence                                                                                                                                       *NPHP1*      290 Kb deletion c.1918delA (p.R640fs)   D                                            --                                                     Unknown                                                  (Hildebrandt et al. [1997](#mgg3206-bib-0023){ref-type="ref"}; Boycott et al. [2008](#mgg3206-bib-0008){ref-type="ref"})

  Oculocutaneous albinism type 1A               203100   Disorder of melanin biosynthesis with generalized reduction in pigmentation of hair, skin and eyes, fovea hypoplasia and optic nerve defect; severely reduced vision                                         *TYR*        c.272G\>A (p.C91Y)                      D,L,S                                        1/9                                                    1/7                                                      (Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"}; Boycott et al. [2008](#mgg3206-bib-0008){ref-type="ref"})

  Sensorineural deafness                        220290   Isolated congenital sensorineural deafness                                                                                                                                                                   *GJB2*       c.35delG (p.G12fs)                      D,S                                          1/65                                                   1/28                                                     (Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"})

  Nonsyndromic mental retardation               614020   Intellectual disability with no associated distinguishing clinical features or metabolic abnormality known                                                                                                   *TECR*       c.545C\>T (p.P182L)                     S                                            1/63                                                   1/14.5                                                   (Caliskan et al. [2011](#mgg3206-bib-0011){ref-type="ref"}; Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"})

  Restrictive dermopathy                        275210   Lethal disorder presenting at birth with characteristic very tense, translucent skin, severe arthrogryposis and lung hypoplasia                                                                              *ZMPSTE24*   c.1085dupT (p.L362fs)                   D,S                                          1/21                                                   1/15.5                                                   (Loucks et al. [2012](#mgg3206-bib-0029){ref-type="ref"}; Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"})

  Segawa syndrome                               605407   Inborn error of metabolism presents as progressive movement disorder with variable dystonia, tremors and abnormal posturing; low CSF neurotransmitters, good response to levodopa; normal intelligence       *TH*         c.1481C\>T (p.T494M)                    D                                            --                                                     Unknown                                                  (Boycott et al. [2008](#mgg3206-bib-0008){ref-type="ref"})

  Sitosterolemia                                210250   Also known as "phytosterolemia", caused by excessive absorption and decreased excretion of plant sterols leading to premature atherosclerosis; responds to ezetimide                                         *ABCG8*      c.320C\>G (p.S107X)                     S                                            1/16                                                   1/12                                                     (Wang et al. [2004](#mgg3206-bib-0037){ref-type="ref"}; Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"})

  Succinylcholine sensitivity                   177400   "pseudocholinesterase" deficiency leads to delayed metabolism of the muscle relaxant drug succinylcholine used in general anesthesia; causes prolonged apnea post operatively                                *BCHE*       c.293A\>G (p.D98G)                      S                                            1/21                                                   Unknown                                                  (Zelinski et al. [2007](#mgg3206-bib-0040){ref-type="ref"})

  Thyroid dyshormonogenesis I                   274400   Congenital hypothyroidism identified on newborn screening by low T4; iodine transport defect; excellent response to treatment                                                                                *SLC5A5*     c.1183G\>A (p.G395R)                    S                                                                                                   Unknown                                                  (Kosugi et al. [1999](#mgg3206-bib-0028){ref-type="ref"})

  Usher syndrome Type 1B                        276900   1 of 2 forms of Usher syndrome seen in Hutterites with congenital sensorineural deafness and progressive visual impairment due to retinitis pigmentosa                                                       *MYO7A*      c.52C\>T (p.Q18X)                       D                                            --                                                     Unknown                                                  (Zhou et al. [2012](#mgg3206-bib-0041){ref-type="ref"})

  Usher syndrome Type 1F                        602083   Similar to Usher syndrome 1B                                                                                                                                                                                 *PCDH15*     c.1103delT (p.L368 fs)                  S                                            1/21                                                   1/40                                                     (Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"}; Alagramam et al. [2001](#mgg3206-bib-0001){ref-type="ref"})

  VLDLR with cerebellar hypoplasia              224050   Early‐onset ataxia and intellectual disability, simplified gyral pattern and distinctive cerebellar hypoplasia                                                                                               *VLDLR*      Deletion of *VLDLR* gene                D,L,S                                        --                                                     1/15                                                     (Boycott et al. [2005](#mgg3206-bib-0006){ref-type="ref"}; Glass et al. [2005](#mgg3206-bib-0020){ref-type="ref"})
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

D‐Dariusleut; L‐Leherleut; S‐Schmeideleut refer to the leuts in which the mutation has been detected.

Carrier frequency observed in samples tested on the chip. Mutations were excluded from the calculation of the carrier frequency if the sample was ascertained as a positive control for that disease.

Indicates the mutation was not detected in any of our samples.

Literature frequency refers to frequencies that have been determined by testing or estimated based on disease incidence and reported in the literature.

Unknown indicates that no estimate of the frequency has been made in the literature to our knowledge.

References to the frequencies in the previous column or the first report of the mutation.

John Wiley & Sons, Ltd

All but one mutation were reliably detected as either wild type, heterozygous, or homozygous. This mutation, *ZMPSTE24* c.1085dupT causing restrictive dermopathy, a lethal disorder, could only be detected as either absent or present with the chip. This is not clinically relevant because if the chip test is positive for restrictive dermopathy, this would indicate heterozygosity of the adult being tested, as individuals with restrictive dermopathy who are homozygous for the *ZMPSTE24* c.1085dupT mutation die early in life (Loucks et al. [2012](#mgg3206-bib-0029){ref-type="ref"}). Nonetheless, further analysis by DNA sequencing would allow a heterozygous and a homozygous genotype to be differentiated in situations where a clinical diagnosis needs to be clarified (Fig. [1](#mgg3206-fig-0001){ref-type="fig"}).

![Sequence of the c.1085dupT mutation in *ZMPSTE24*. Sequencing of the region differentiated the heterozygous (Het) and homozygous (Hom) samples for the c.1085dupT.](MGG3-4-312-g001){#mgg3206-fig-0001}

In addition to the mutations that were expected in the 59 control samples, on average, 1.2 additional mutations were identified. Three samples were homozygous for diseases other than that for which they served as a positive control, including two affected with Joubert syndrome‐related disorder and one with limb girdle muscular dystrophy type 2I. More than one disease diagnosis may have already been documented as present in these individuals, but because the samples were de‐identified, this was not possible to follow‐up.

To test the sensitivity of the chip, 12 Schmiedeleut Hutterite samples, that had previously been sequenced or tested for a number of mutations as part of previous studies, were submitted in a blinded fashion to Asper for testing (Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"}). In total, 10 different mutations were identified in these samples. All but one mutation, where a lack of DNA prevented its validation, was confirmed to be present by comparison to previous whole genome sequencing, previous genotyping results, or through a secondary method. No mutations that had previously been identified by another method were missed by the chip. Overall, there was a 100% concordance of the chip results with the results of other methods.

When mutations additional to those expected in the 59 control samples were combined with those identified in the 12 additional samples used to test the sensitivity of the chip, it became clear that the carrier frequencies of the different mutations were variable in our samples (Table [1](#mgg3206-tbl-0001){ref-type="table-wrap"}). We decided to compare the results to those of previous studies where a carrier frequency had been estimated (Table [1](#mgg3206-tbl-0001){ref-type="table-wrap"}) in order to identify any obvious discrepancies, and to provide new information where none was previously available. One obvious difference was the absence of the *VLDLR* gene deletion in our samples when it had previously been estimated to have a carrier frequency of 1/15 in the Alberta Hutterites (Dariusleut and Lehrerleut) (Glass et al. [2005](#mgg3206-bib-0020){ref-type="ref"}). The absence of the *VLDLR* deletion was therefore confirmed in the 12 anonymous samples by a second method, and this discordance may reflect a lower carrier rate in the Schmiedeleut Hutterite population.

Discussion {#mgg3206-sec-0013}
==========

We have developed a reliable tool for carrier screening of 30 autosomal recessive conditions in the Hutterite population. Further, additional mutations can be added to this chip as new mutations are identified. This test is currently available through Asper Biotech and is quite affordable at \$235 EUR (\~\$250 USD). Given that the price of testing a single known mutation is similar at \$250 USD, the use of the chip to interrogate 32 mutations simultaneously is highly cost‐effective. We anticipate that this test will primarily be used on a voluntary basis for adult individuals who are considering marriage or for couples planning a family. It might also be used in unique situations where the diagnosis of a previously affected child is unclear or if multiple diseases on the chip are part of a differential diagnosis for an affected individual.

This chip, although broad in scope, does not currently provide comprehensive carrier screening for the Hutterite population. One of the clinically significant autosomal recessive diseases with a high carrier frequency that was not included is spinal muscular atrophy (SMA). A founder haplotype for SMA in Hutterites has been described that could be identified using 26 single‐nucleotide polymorphisms (Chong et al. [2011](#mgg3206-bib-0012){ref-type="ref"}). Unfortunately, our resources at the time of development did not allow the incorporation of this test onto the chip. Also, the molecular basis of Maple Syrup Urine Disease, BCKDHB gene, c.595_596delAG (Mroch et al. [2014](#mgg3206-bib-0032){ref-type="ref"}), and a second Joubert‐like condition resulting from mutations in *CSSP1*(Shaheen et al. [2014](#mgg3206-bib-0036){ref-type="ref"}) were recently reported and could now be added. No doubt additional mutations will continue to be identified that could make this an even more comprehensive test.

Among the disorders tested on this chip, several are relatively unique to the Hutterite population. For example, Bowen--Conradi syndrome, limb girdle muscular dystrophy type 2H, dilated cardiomyopathy with ataxia, Beaulieu‐Boycott‐Innes syndrome, and nonsyndromic mental retardation due to *TERC1* mutations have not, or rarely been molecularly confirmed in non‐Hutterites. In the case of Bowen--Conradi syndrome, no mutation in *EMG1* has been found in non‐Hutterite infants, who were thought to have the condition based on clinical presentation (Triggs‐Raine et al., unpubl.data). Further, many of the mutations in Table [1](#mgg3206-tbl-0001){ref-type="table-wrap"} are unique to the Hutterite population, reflecting their unique founder ancestry.

The Hutterites, together with the Mennonites and Amish, arose during the Protestant Reformation in central Europe. These groups were derived during the 16th and 17th centuries from similar ancestral populations, and thus it is not surprising that some mutations are shared between these populations. A summary of the disorders found in the Anabaptist groups is at <http://www.biochemgenetics.ca/plainpeople/>(Payne et al. [2011](#mgg3206-bib-0034){ref-type="ref"}). As an example, the c.1085dupT mutation in *ZMPSTE24* that was reported in Old Colony Mennonites is also recently reported in Hutterites (Loucks et al. [2012](#mgg3206-bib-0029){ref-type="ref"}). Similarly, the c.1001G\>A mutation in *ALPL* was originally found to cause hypophosphatasia in Mennonites (Greenberg et al. [1993](#mgg3206-bib-0021){ref-type="ref"}) and subsequently detected in at least one Hutterite infant.

Many of the mutations on the CHIP were identified in one or more of the positive controls and/or anonymous samples that we tested (Table [1](#mgg3206-tbl-0001){ref-type="table-wrap"}). One unexpected finding was a high carrier frequency (1/13) for the c.393dupA mutation in *NDUFS4* causing Leigh syndrome. Given this finding, it would be important for physicians who work with the Hutterite population to consider this disease on the differential diagnosis in infants presenting with progressive neurodegeneration. The carrier frequency for succinylcholine sensitivity was also unknown, and this study suggests a frequency of approximately 1/21 Hutterites. As a result of this relatively high carrier frequency, the use of succinylcholine in induction of general anesthesia is avoided in children of Hutterite descent at the Health Sciences Centre in Manitoba. The majority of the control and anonymized samples were from the Schmiedeleut and Dariusleut groups, therefore resulting in a bias toward detecting the mutations in those leut (Table [1](#mgg3206-tbl-0001){ref-type="table-wrap"}). In fact, 10 mutations were not identified in either our controls or anonymous samples, suggesting that these mutations may have a low carrier rate, or that they are private to the Lehrerleut.

A comprehensive study of the changes in the frequency of autosomal recessive disease‐causing mutations in the Schmiedeleut population demonstrated an increase in the frequency of some disease‐causing mutations (Chong et al. [2012](#mgg3206-bib-0013){ref-type="ref"}). The release of the results of this study indicated that Hutterite individuals want carrier information (Anderson et al. [2014](#mgg3206-bib-0002){ref-type="ref"}), consistent with the interest expressed by Schmiedeleut Hutterites in Manitoba. Although future research is needed to assess the impact of comprehensive carrier testing in the population, it is clear that this approach has the potential to provide information that will empower this group.
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